• Consensus Rating: Buy
  • Consensus Price Target: $57.88
  • Forecasted Upside: 76.61%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$32.77
▼ -0.24 (-0.73%)

This chart shows the closing price for ATRC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AtriCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRC

Analyst Price Target is $57.88
▲ +76.61% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for AtriCure in the last 3 months. The average price target is $57.88, with a high forecast of $74.00 and a low forecast of $42.00. The average price target represents a 76.61% upside from the last price of $32.77.

This chart shows the closing price for ATRC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in AtriCure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2024UBS GroupBoost TargetBuy ➝ Buy$57.00 ➝ $58.00Low
2/16/2024Stifel NicolausLower TargetBuy ➝ Buy$50.00 ➝ $42.00Low
2/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$44.00 ➝ $46.00Low
1/4/2024Needham & Company LLCLower TargetBuy ➝ Buy$49.00 ➝ $44.00Low
11/29/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$60.00Low
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$49.00Low
11/2/2023Needham & Company LLCLower TargetBuy ➝ Buy$68.00 ➝ $49.00Low
11/2/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$60.00 ➝ $50.00N/A
10/23/2023JMP SecuritiesInitiated CoverageOutperform$60.00Low
9/29/2023UBS GroupInitiated CoverageBuy$56.00Low
7/26/2023Piper SandlerBoost Target$55.00 ➝ $65.00Low
7/26/2023Stifel NicolausBoost Target$50.00 ➝ $59.00Low
7/26/2023BTIG ResearchBoost Target$56.00 ➝ $68.00Low
7/26/2023Needham & Company LLCBoost TargetBuy$60.00 ➝ $68.00Low
7/17/2023BTIG ResearchBoost Target$55.00 ➝ $56.00Low
5/3/2023Needham & Company LLCBoost Target$58.00 ➝ $60.00Low
5/3/2023Stifel NicolausBoost Target$48.00 ➝ $50.00Low
4/17/2023Needham & Company LLCReiterated RatingBuy$58.00Low
2/22/2023Canaccord Genuity GroupLower TargetBuy$81.00 ➝ $74.00Low
2/22/2023BTIG ResearchLower TargetBuy$65.00 ➝ $55.00Low
2/22/2023Stifel NicolausLower TargetBuy$55.00 ➝ $48.00Low
2/22/2023Needham & Company LLCReiterated RatingBuy$58.00Low
12/19/2022Needham & Company LLCBoost TargetBuy$55.00 ➝ $58.00Low
11/2/2022Canaccord Genuity GroupLower Target$72.00 ➝ $65.00Low
11/2/2022Needham & Company LLCLower Target$65.00 ➝ $55.00Low
10/17/2022BTIG ResearchLower TargetBuy$75.00 ➝ $71.00Low
8/3/2022Piper SandlerLower TargetOverweight$90.00 ➝ $55.00Low
8/3/2022Needham & Company LLCBoost TargetBuy$55.00 ➝ $65.00Low
7/18/2022Stifel NicolausLower Target$70.00 ➝ $50.00Low
6/28/2022Needham & Company LLCLower TargetBuy$67.00 ➝ $55.00Low
6/24/2022BTIG ResearchLower TargetBuy$94.00 ➝ $75.00Low
5/4/2022Needham & Company LLCLower Target$79.00 ➝ $67.00High
3/14/2022BTIG ResearchReiterated RatingBuy$94.00Medium
2/24/2022Needham & Company LLCReiterated RatingBuy$79.00High
2/16/2022Canaccord Genuity GroupLower Target$120.00 ➝ $88.00High
2/16/2022Needham & Company LLCLower TargetBuy$92.00 ➝ $79.00High
11/4/2021SVB LeerinkBoost TargetOutperform$100.00 ➝ $110.00High
11/4/2021Needham & Company LLCBoost TargetBuy$90.00 ➝ $92.00High
8/5/2021Needham & Company LLCLower TargetBuy$91.00 ➝ $90.00High
8/5/2021SVB LeerinkBoost TargetOutperform$95.00 ➝ $100.00High
8/5/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
6/15/2021Stifel NicolausBoost TargetPositive ➝ Buy$72.00 ➝ $85.00High
5/26/2021SVB LeerinkBoost TargetOutperform$78.00 ➝ $95.00High
5/17/2021Needham & Company LLCReiterated RatingBuy$91.00High
5/14/2021JPMorgan Chase & Co.Boost TargetOverweight$70.00 ➝ $81.00Low
4/29/2021Piper SandlerBoost Target$70.00 ➝ $85.00Medium
4/29/2021SVB LeerinkReiterated RatingBuyHigh
4/28/2021Needham & Company LLCBoost TargetBuy$74.00 ➝ $81.00High
4/28/2021OppenheimerBoost TargetOutperform$65.00 ➝ $75.00High
4/28/2021BTIG ResearchBoost TargetBuy$69.00 ➝ $76.00High
2/24/2021SVB LeerinkBoost TargetOutperform$65.00 ➝ $78.00Low
2/24/2021Needham & Company LLCBoost TargetBuy$63.00 ➝ $74.00High
1/29/2021Piper SandlerBoost TargetOverweight$50.00 ➝ $66.00Medium
1/21/2021BTIG ResearchBoost TargetIn-Line ➝ Buy$56.00 ➝ $66.00Low
12/18/2020Needham & Company LLCBoost TargetBuy$53.00 ➝ $63.00High
12/14/2020SVB LeerinkBoost TargetOutperform$60.00 ➝ $65.00High
11/6/2020Needham & Company LLCLower TargetBuy$63.00 ➝ $53.00Medium
7/29/2020JPMorgan Chase & Co.Boost TargetOverweight$48.00 ➝ $57.00High
7/29/2020SVB LeerinkBoost TargetOutperform$55.00 ➝ $60.00High
7/29/2020Piper SandlerBoost TargetPositive ➝ Overweight$47.00 ➝ $50.00High
7/28/2020BTIG ResearchReiterated RatingBuy$56.00High
5/11/2020BTIG ResearchBoost TargetBuy$45.00 ➝ $56.00High
5/11/2020SVB LeerinkBoost TargetOutperform$50.00 ➝ $55.00High
5/11/2020OppenheimerBoost TargetOutperform$45.00 ➝ $52.00High
5/8/2020Needham & Company LLCReiterated RatingBuy$49.00Medium
4/29/2020BTIG ResearchReiterated RatingBuy$45.00High
4/28/2020JPMorgan Chase & Co.Lower TargetOverweight$47.00 ➝ $39.00Medium
4/19/2020OppenheimerInitiated CoverageOutperform$45.00Low
4/6/2020OppenheimerInitiated CoverageOutperform$45.00High
2/19/2020Piper SandlerBoost Target$40.00 ➝ $50.00Medium
2/19/2020Needham & Company LLCBoost TargetBuy$48.00 ➝ $52.00High
2/19/2020BTIG ResearchBoost TargetBuy$42.00 ➝ $48.00High
2/6/2020BTIG ResearchInitiated CoverageBuy$42.00Medium
1/27/2020Piper SandlerReiterated RatingBuy$40.00High
1/24/2020Needham & Company LLCReiterated RatingBuy$39.00 ➝ $48.00Low
1/21/2020BTIG ResearchReiterated RatingBuy ➝ Outperform$42.00Low
9/6/2019JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/13/2019BTIG ResearchReiterated RatingBuy$35.00High
8/13/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$30.00High
8/12/2019Piper Sandler CompaniesSet TargetBuy$40.00Medium
8/12/2019Needham & Company LLCSet TargetBuy$39.00Medium
4/26/2019Northland SecuritiesReiterated RatingBuyHigh
4/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$37.00Medium
4/2/2019BTIG ResearchUpgradeNeutral ➝ Buy$35.00High
3/28/2019Needham & Company LLCReiterated RatingBuy$39.00High
3/5/2019BTIG ResearchReiterated RatingHoldLow
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/26/2023
  • 14 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 10 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
11/23/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
12/23/2023
  • 7 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/22/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/21/2024

Current Sentiment

  • 7 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $32.77
Low: $32.69
High: $33.11

50 Day Range

MA: $34.32
Low: $31.71
High: $37.31

52 Week Range

Now: $32.77
Low: $29.67
High: $59.61

Volume

23,184 shs

Average Volume

554,839 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of AtriCure?

The following Wall Street research analysts have issued reports on AtriCure in the last year: BTIG Research, Canaccord Genuity Group Inc., JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Stifel Nicolaus, StockNews.com, and UBS Group AG.
View the latest analyst ratings for ATRC.

What is the current price target for AtriCure?

8 Wall Street analysts have set twelve-month price targets for AtriCure in the last year. Their average twelve-month price target is $57.88, suggesting a possible upside of 76.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting ATRC will reach $74.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $42.00 for AtriCure in the next year.
View the latest price targets for ATRC.

What is the current consensus analyst rating for AtriCure?

AtriCure currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATRC will outperform the market and that investors should add to their positions of AtriCure.
View the latest ratings for ATRC.

What other companies compete with AtriCure?

How do I contact AtriCure's investor relations team?

AtriCure's physical mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company's listed phone number is (513) 755-4100 and its investor relations email address is [email protected]. The official website for AtriCure is www.atricure.com. Learn More about contacing AtriCure investor relations.